Summit Tx Capital, L.P. Dyne Therapeutics, Inc. Transaction History
Summit Tx Capital, L.P.
- $2.32 Trillion
- Q2 2025
A detailed history of Summit Tx Capital, L.P. transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Summit Tx Capital, L.P. holds 118,961 shares of DYN stock, worth $1.5 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
118,961
Previous 129,858
8.39%
Holding current value
$1.5 Million
Previous $1.36 Billion
16.62%
% of portfolio
0.05%
Previous 0.06%
Shares
2 transactions
Others Institutions Holding DYN
# of Institutions
211Shares Held
122MCall Options Held
36.5KPut Options Held
74.3K-
Ra Capital Management, L.P. Boston, MA9.71MShares$123 Million2.02% of portfolio
-
Janus Henderson Group PLC London, X09.44MShares$119 Million0.05% of portfolio
-
Atlas Venture Life Science Advisors, LLC9.13MShares$115 Million19.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.65MShares$96.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$93.2 Million0.01% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $653M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...